Suvoda Partners with Bolt to Enhance Clinical Trial Transportation for Patients Across the EU

Suvoda and Bolt Join Forces to Improve Clinical Trial Mobility

In an important development for clinical trials in Europe, Suvoda has announced a strategic partnership with Bolt Business, a leading European mobility company, to enhance transportation options for patients participating in clinical trials. This collaboration is designed to provide more accessible and affordable travel solutions to trial participants across the European Union, thereby reducing logistical and financial stress involved in the clinical trial process.

Suvoda, a global clinical trial technology company recently merged with Greenphire, has positioned itself at the forefront of addressing the complex challenges faced in clinical trials. With this new agreement, clinical trial travel specialists within Suvoda will be able to coordinate rides through Bolt for their patients without requiring out-of-pocket expenses. This initiative not only relieves the financial burden on participants but also helps maintain their focus on the trial itself, ensuring better retention rates essential for the success of these studies.

Impact on Clinical Trial Participation

Managing transport logistics has often been a challenging aspect of clinical trials. As patients already encounter numerous health-related difficulties when participating in these trials, the last thing they need is to face additional transportation challenges. According to Will Wing, Suvoda's Director of Product and Travel, "Our collaboration with Bolt Business removes barriers to patient travel, helping them stay engaged in their trial, which is crucial for both the centers and sponsors that depend on consistent patient participation."

This partnership offers a reliable and cost-effective alternative to traditional transport services, while also upholding high standards for data privacy and security. This will significantly improve access for patients from diverse backgrounds who are involved in clinical trials.

Suvoda and Bolt Business share a commitment to eliminating barriers faced by clinical trial participants. This agreement facilitates flexible transport solutions within the EU markets, giving Suvoda control over costs and the necessary account management support. Liam James, Account Manager at Bolt Business, states, "With Bolt's mobility options available, we are helping patients to focus on their health."

Continuing Commitment to Global Clinical Trials

The partnership with Bolt is the latest embodiment of Suvoda's ongoing investment in enhancing travel experiences for clinical trial participants globally. They already support over 8,400 sites participating in more than 2,000 studies across over 50 countries, showcasing a robust and committed model of patient support.

Their services include a personalized care model with over 90 dedicated concierges focused on supporting participants involved in rare and ultra-rare disease trials, boasting a remarkable 90% satisfaction rate among global centers. This new partnership follows Suvoda's successful merger with Greenphire in March 2025, which aimed to consolidate leading technologies in randomization, clinical supply management, patient consent, engagement, financial support, and travel into one unified platform.

By integrating advanced software solutions and industry-leading services, Suvoda aims to tackle the most pressing and complex challenges in clinical trials, ensuring that life-changing studies can progress, even in the most urgent situations.

About Suvoda

Suvoda is a global clinical trial technology company that provides a real-time operational platform which enables sponsors and CROs to make confident decisions while allowing sites and patients to operate with ease and control. They pride themselves on delivering interconnected, actionable software solutions and industry-leading support services, contributing to high customer satisfaction levels that consistently exceed industry benchmarks. Currently, the company supports over 2,000 trials in more than 95 countries. For additional information, please visit suvoda.com or follow Suvoda on LinkedIn.